NCT06184360View on ClinicalTrials.gov

Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)

CompletedOBSERVATIONAL
Enrollment

2,079

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

June 30, 2022

Study Completion Date

December 16, 2022

Conditions
Neovascular (Wet) Age-related Macular Degeneration
Trial Locations (1)

07936

Novartis, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY